Trial Profile

Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tusamitamab ravtansine (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Acronyms TusaRav-QT
Sponsors Sanofi

Most Recent Events

10 Apr 2024 Status changed from active, no longer recruiting to discontinued. (Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial didnot meet dual primary endpoint of improving progression-free survival. The decision is notrelated to any safety concern.)
06 Sep 2023 Planned End Date changed from 3 Dec 2024 to 1 Aug 2024.
06 Sep 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com